AER 1598682 is a spontaneous case, received on 23/Jun/2015 from a physician and concerns a 67 year old male 
patient who developed progressive multifocal leukoencephalopathy whilst being treated with rituximab (Mabthera).
Patient's medical history, concurrent conditions, concomitant medications and past drugs were not reported.
On an unknown date in Aug/2013, the patient started therapy with rituximab (dosage regimen not provided) for non 
hodgkin's lymphoma. On 04/May/2015,he received most recent dose of rituximab prior to AE onset. On 
05/Jun/2015, he was diagnosed with progressive multifocal leukoencephalopathy, JC-virus (John Cunningham 
virus) was proved in serum and liquor.
Print Time: 13-JUN-2016 09:36 AM If a field is blank, there is no data for that field Page 58 of 457
FDA - Adverse Event Reporting System (FAERS) 
FOIA Case Report Information
At the time of the report, outcome of the event progressive multifocal leukoencephalopathy was persisting and it 
was unknown whether therapy with rituximab was ongoing or not.
The physician did not assess causal relationship of the event progressive multifocal leukoencephalopathy with 
rituximab.
The company assessed the event progressive multifocal leukoencephalopathy as medically significant. 
No further information was provided.
This confirmed case of progressive multifocal leukoencephalopathy (PML) is being expedited per 
Roche/Genentech Enhanced Pharmacovigilance Plan for PML